JP7254094B2 - Ｐｒｍｔ５阻害剤としての置換イミダゾリジン－２－オン誘導体 - Google Patents
Ｐｒｍｔ５阻害剤としての置換イミダゾリジン－２－オン誘導体 Download PDFInfo
- Publication number
- JP7254094B2 JP7254094B2 JP2020549740A JP2020549740A JP7254094B2 JP 7254094 B2 JP7254094 B2 JP 7254094B2 JP 2020549740 A JP2020549740 A JP 2020549740A JP 2020549740 A JP2020549740 A JP 2020549740A JP 7254094 B2 JP7254094 B2 JP 7254094B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cancer
- lymphoma
- methyl
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023052481A JP2023082088A (ja) | 2018-03-22 | 2023-03-28 | Ｐｒｍｔ５阻害剤としての置換イミダゾリジン－２－オン誘導体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201841010656 | 2018-03-22 | ||
| IN201841010656 | 2018-03-22 | ||
| PCT/IB2019/052252 WO2019180631A1 (en) | 2018-03-22 | 2019-03-20 | Substituted imidazolidin-2-one derivatives as prmt5 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023052481A Division JP2023082088A (ja) | 2018-03-22 | 2023-03-28 | Ｐｒｍｔ５阻害剤としての置換イミダゾリジン－２－オン誘導体 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021518366A JP2021518366A (ja) | 2021-08-02 |
| JPWO2019180631A5 JPWO2019180631A5 (https=) | 2022-03-29 |
| JP2021518366A5 JP2021518366A5 (https=) | 2022-03-29 |
| JP7254094B2 true JP7254094B2 (ja) | 2023-04-07 |
Family
ID=67986029
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020549740A Active JP7254094B2 (ja) | 2018-03-22 | 2019-03-20 | Ｐｒｍｔ５阻害剤としての置換イミダゾリジン－２－オン誘導体 |
| JP2023052481A Pending JP2023082088A (ja) | 2018-03-22 | 2023-03-28 | Ｐｒｍｔ５阻害剤としての置換イミダゾリジン－２－オン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023052481A Pending JP2023082088A (ja) | 2018-03-22 | 2023-03-28 | Ｐｒｍｔ５阻害剤としての置換イミダゾリジン－２－オン誘導体 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11542275B2 (https=) |
| EP (1) | EP3768671B1 (https=) |
| JP (2) | JP7254094B2 (https=) |
| KR (1) | KR102767362B1 (https=) |
| CN (1) | CN112105609A (https=) |
| AU (1) | AU2019237329B2 (https=) |
| BR (1) | BR112020019111A2 (https=) |
| CA (1) | CA3092770A1 (https=) |
| CU (1) | CU24627B1 (https=) |
| EA (1) | EA202092253A1 (https=) |
| ES (1) | ES2982859T3 (https=) |
| IL (1) | IL277518B2 (https=) |
| MX (1) | MX2020009738A (https=) |
| MY (1) | MY203159A (https=) |
| PH (1) | PH12020551494A1 (https=) |
| SG (1) | SG11202008526VA (https=) |
| WO (1) | WO2019180631A1 (https=) |
| ZA (1) | ZA202006137B (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3768670A4 (en) * | 2018-03-22 | 2021-11-24 | Aurigene Discovery Technologies Limited | IMIDAZOLIDIN-2-ONE COMPOUNDS AS PRMT5 MODULATORS |
| EP3768671B1 (en) * | 2018-03-22 | 2024-05-22 | Aurigene Oncology Limited | Substituted imidazolidin-2-one derivatives as prmt5 inhibitors |
| US11077101B1 (en) | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
| WO2021086879A1 (en) | 2019-10-28 | 2021-05-06 | Tango Therapeutics, Inc. | Compounds and methods of use |
| CN116568677A (zh) | 2020-07-31 | 2023-08-08 | 探戈医药股份有限公司 | 可用于治疗mtap缺乏和/或mta累积癌症的哌啶-1-基-n-吡啶-3-基-2-氧代乙酰胺衍生物 |
| CN116940571A (zh) * | 2021-03-15 | 2023-10-24 | 诺华股份有限公司 | 苯并异噁唑衍生物及其用途 |
| CN115232147B (zh) * | 2022-08-09 | 2023-10-13 | 南方科技大学 | 一种作为HIF-2α激动剂的杂环衍生物 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012530763A (ja) | 2009-06-26 | 2012-12-06 | ノバルティス アーゲー | Ｃｙｐ１７阻害剤としての１，３−二置換イミダゾリジン−２−オン誘導体 |
| JP2014512411A (ja) | 2011-04-28 | 2014-05-22 | ノバルティス アーゲー | １７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤 |
| WO2014108820A1 (en) | 2013-01-08 | 2014-07-17 | Aurigene Discovery Technologies Limited | Substituted 2-pyrazinone derivatives as kinase inhibitors |
| JP2016505001A (ja) | 2012-12-21 | 2016-02-18 | エピザイム，インコーポレイティド | Ｐｒｍｔ５阻害剤およびその使用 |
| JP2016505596A (ja) | 2012-12-21 | 2016-02-25 | エピザイム，インコーポレイティド | Ｐｒｍｔ５阻害剤およびその使用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69729583T2 (de) * | 1996-04-17 | 2005-06-09 | Bristol-Myers Squibb Pharma Co. | N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-on derivative als faktor xa inhibitoren |
| IN2012CH00067A (https=) * | 2012-01-06 | 2017-08-04 | ||
| CA2894157A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| EP3406607A1 (en) | 2012-12-21 | 2018-11-28 | Epizyme, Inc. | Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
| JP2016511744A (ja) | 2012-12-21 | 2016-04-21 | エピザイム，インコーポレイティド | Ｐｒｍｔ５を阻害する方法 |
| GB201302927D0 (en) | 2013-02-20 | 2013-04-03 | Cancer Therapeutics Crc Pty Ltd | Compounds |
| JP6510485B2 (ja) | 2013-03-15 | 2019-05-08 | オハイオ・ステイト・イノベーション・ファウンデーション | Ｐｒｍｔ５インヒビターおよびそれらの使用方法 |
| TWI690521B (zh) * | 2014-04-07 | 2020-04-11 | 美商同步製藥公司 | 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類 |
| WO2015200680A2 (en) | 2014-06-25 | 2015-12-30 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| EP3160466A4 (en) | 2014-06-25 | 2017-12-27 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| EP3177288A4 (en) | 2014-08-04 | 2018-04-04 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| GB201415573D0 (en) | 2014-09-03 | 2014-10-15 | Cancer Therapeutics Crc Pty Ltd | Compounds |
| GB201604027D0 (en) * | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| GB201604020D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| EP3266784A1 (en) | 2016-06-08 | 2018-01-10 | Pierre Fabre Medicament | Protein arginine n-methyltransferases inhibitors and uses thereof |
| EP3768671B1 (en) * | 2018-03-22 | 2024-05-22 | Aurigene Oncology Limited | Substituted imidazolidin-2-one derivatives as prmt5 inhibitors |
-
2019
- 2019-03-20 EP EP19771397.7A patent/EP3768671B1/en active Active
- 2019-03-20 SG SG11202008526VA patent/SG11202008526VA/en unknown
- 2019-03-20 CN CN201980029962.0A patent/CN112105609A/zh active Pending
- 2019-03-20 CA CA3092770A patent/CA3092770A1/en active Pending
- 2019-03-20 WO PCT/IB2019/052252 patent/WO2019180631A1/en not_active Ceased
- 2019-03-20 BR BR112020019111-6A patent/BR112020019111A2/pt unknown
- 2019-03-20 US US16/982,800 patent/US11542275B2/en active Active
- 2019-03-20 EA EA202092253A patent/EA202092253A1/ru unknown
- 2019-03-20 AU AU2019237329A patent/AU2019237329B2/en active Active
- 2019-03-20 MY MYPI2020004843A patent/MY203159A/en unknown
- 2019-03-20 IL IL277518A patent/IL277518B2/en unknown
- 2019-03-20 JP JP2020549740A patent/JP7254094B2/ja active Active
- 2019-03-20 CU CU2020000067A patent/CU24627B1/es unknown
- 2019-03-20 MX MX2020009738A patent/MX2020009738A/es unknown
- 2019-03-20 KR KR1020207030078A patent/KR102767362B1/ko active Active
- 2019-03-20 ES ES19771397T patent/ES2982859T3/es active Active
-
2020
- 2020-09-17 PH PH12020551494A patent/PH12020551494A1/en unknown
- 2020-10-02 ZA ZA2020/06137A patent/ZA202006137B/en unknown
-
2023
- 2023-03-28 JP JP2023052481A patent/JP2023082088A/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012530763A (ja) | 2009-06-26 | 2012-12-06 | ノバルティス アーゲー | Ｃｙｐ１７阻害剤としての１，３−二置換イミダゾリジン−２−オン誘導体 |
| JP2014512411A (ja) | 2011-04-28 | 2014-05-22 | ノバルティス アーゲー | １７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤 |
| JP2016505001A (ja) | 2012-12-21 | 2016-02-18 | エピザイム，インコーポレイティド | Ｐｒｍｔ５阻害剤およびその使用 |
| JP2016505596A (ja) | 2012-12-21 | 2016-02-25 | エピザイム，インコーポレイティド | Ｐｒｍｔ５阻害剤およびその使用 |
| WO2014108820A1 (en) | 2013-01-08 | 2014-07-17 | Aurigene Discovery Technologies Limited | Substituted 2-pyrazinone derivatives as kinase inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019237329A1 (en) | 2020-10-01 |
| CN112105609A (zh) | 2020-12-18 |
| CU24627B1 (es) | 2022-11-07 |
| ZA202006137B (en) | 2025-11-26 |
| SG11202008526VA (en) | 2020-10-29 |
| EP3768671A1 (en) | 2021-01-27 |
| KR20200135827A (ko) | 2020-12-03 |
| KR102767362B1 (ko) | 2025-02-13 |
| JP2023082088A (ja) | 2023-06-13 |
| MY203159A (en) | 2024-06-12 |
| MX2020009738A (es) | 2020-10-08 |
| CU20200067A7 (es) | 2021-04-07 |
| EP3768671A4 (en) | 2021-11-24 |
| AU2019237329B2 (en) | 2024-03-28 |
| CA3092770A1 (en) | 2019-09-26 |
| ES2982859T3 (es) | 2024-10-17 |
| IL277518A (en) | 2020-11-30 |
| EP3768671C0 (en) | 2024-05-22 |
| BR112020019111A2 (pt) | 2021-01-12 |
| JP2021518366A (ja) | 2021-08-02 |
| EA202092253A1 (ru) | 2021-01-14 |
| IL277518B2 (en) | 2024-01-01 |
| WO2019180631A1 (en) | 2019-09-26 |
| EP3768671B1 (en) | 2024-05-22 |
| US20210002298A1 (en) | 2021-01-07 |
| US11542275B2 (en) | 2023-01-03 |
| IL277518B1 (en) | 2023-09-01 |
| PH12020551494A1 (en) | 2021-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7254094B2 (ja) | Ｐｒｍｔ５阻害剤としての置換イミダゾリジン－２－オン誘導体 | |
| JP7487421B2 (ja) | Ｐｒｍｔ５阻害剤 | |
| CN109952295B (zh) | 一种cdk4/6抑制剂及其制备方法和应用 | |
| KR102089239B1 (ko) | Dna-pk 억제제 | |
| JP2023511337A (ja) | ピリミジン－４（３ｈ）－オンヘテロ環式化合物、その調製方法、およびその医薬的使用 | |
| CN107635986A (zh) | 取代的喹喔啉衍生物 | |
| US11365205B2 (en) | Imidazolidin-2-one compounds as PRMT5 modulators | |
| JP2018502141A (ja) | キナゾリン及びキノリン化合物、ならびにその使用 | |
| CN114555597A (zh) | 异柠檬酸脱氢酶（idh）抑制剂 | |
| HK40043100B (en) | Substituted imidazolidin-2-one derivatives as prmt5 inhibitors | |
| HK40043100A (en) | Substituted imidazolidin-2-one derivatives as prmt5 inhibitors | |
| CN116888120B (zh) | Prmt5抑制剂 | |
| EA046513B1 (ru) | Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5 | |
| KR20260039689A (ko) | Wee1 a 인산화효소 억제 방법에 사용하기 위한 피라졸로-피리미딘온 화합물 | |
| CN120858099A (zh) | Cdk抑制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220317 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220317 |
|
| TRDD | Decision of grant or rejection written | ||
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230216 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230301 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230328 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7254094 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |